NanoDx Tbit System

About NanoDx

NanoDx is pioneering a novel point-of-care diagnostic platform that leverages patented nanowire biosensor technology licensed from Harvard University and IBM. The company's core value proposition is enabling rapid, accurate, and multiplexed biomarker detection at the patient's side, aiming to accelerate treatment decisions and reduce healthcare costs. Its lead program targets Traumatic Brain Injury (TBI) and has received FDA Breakthrough Device Designation, positioning it as a potential first-to-market solution. As a private, pre-revenue company, NanoDx is developing an expandable platform with a strategy to address a wide range of future diagnostic applications across various care settings.

Therapeutic Areas